Marie Passet

Paris, 75010, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 28 publications

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Splicing-associated network PAK1-CLK1/4-SRRM1 is a vulnerability to overcome chemoresistance in human and mouse acute myeloid leukemia.

Journal: Science translational medicine
Published: July 08, 2026

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia.

Predisposition to ALL and Solid Tumors Rather Than Bone Marrow Failure in FANCM-Associated Fanconi Anemia.

Journal: JCO precision oncology
Published: March 25, 2026

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Persistent BCR::ABL1-positive preleukemic stem cells drive late clonal evolution in Philadelphia chromosome-positive ALL.

Journal: HemaSphere
Published: March 11, 2026

From a novel pathogenic SAMD9L variant to cohort-wide insights: Whole-genome sequencing highlights somatic genetic rescue and phenotypic heterogeneity.

From a novel pathogenic SAMD9L variant to cohort-wide insights: Whole-genome sequencing highlights somatic genetic rescue and phenotypic heterogeneity.

Journal: British journal of haematology
Published: March 05, 2026

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

CEBP and ZEB2 alterations define three distinct subtypes of B-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: February 01, 2026

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Blinatumomab consolidation for high-risk Ph- B-cell acute lymphoblastic leukemia: the GRAALL-2014/B-QUEST study.

Journal: Blood
Published: January 20, 2026

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Blinatumomab Consolidation for High-Risk Ph-negative B-cell Acute Lymphoblastic Leukemia: the GRAALL-2014/B-QUEST Study.

Journal: Blood
Published: January 20, 2026

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

IGH::FENDRR and specific KRAS mutations define a novel B-ALL molecular subtype with poor chemotherapy response.

Journal: Blood
Published: August 14, 2025

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Significance of Measurable Residual Disease in Adult Philadelphia Chromosome-Positive ALL: A GRAAPH-2014 Study.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 19, 2024

Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort.

Inflammatory Waldenström macroglobulinemia is associated with clonal hematopoiesis: a multicentric cohort.

Journal: Blood
Published: June 14, 2024

Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.

Genetic subtypes of B-cell acute lymphoblastic leukemia in adults.

Journal: Blood
Published: June 03, 2024
Showing 1-12 of 28

Last Updated: 09/26/2026